Press Releases

Press Releases

DateTitle 
Dec 06, 2020
Updated interim   d ata from CPI-818 ’s   p hase 1/1b c linical t rial provide evidence supporting its potential as a treatment for T cell lymphomas New pre-clinical data provide evidence of CPI-818   potential as a treatment for   autoimmune lymphoproliferative syndrome (ALPS) BURLINGAME, Calif.
Nov 30, 2020
Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS) BURLINGAME, Calif. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today
Nov 11, 2020
Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2 Plans to initiate pivotal , randomized , double blind trial in December with results expected mid - 2021 BURLINGAME, Calif. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.
Nov 09, 2020
Data to be presented in a poster and an oral session “ Hot Topic Symposium : COVID-19 and Cancer ” at SITC Anti-SARS-COV-2 antibody response (IgG and IgM) to trimeric spike protein and RBD of SARS-CoV-2. Patients received a 0.3, 1.0 or 3.0 mg/kg single dose of CPI-006 and antibody titers were
Nov 02, 2020
Company to host R&D Symposium webcast on November 12, 2020 at 11:00 am ET to highlight COVID-19 program and provide updates on its cancer programs BURLINGAME, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today
Oct 29, 2020
BURLINGAME, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the third quarter ended September 30, 2020 .
Oct 29, 2020
Company to host R&D Symposium webcast November 12, 2020 at 11:00 am ET to highlight COVID-19 program and provide updates on its cancer programs BURLINGAME, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today
Oct 05, 2020
Angel ’s   pipeline will feature Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and its preclinical BTK inhibitor program Strategic collaboration gives Corvus 49.7% equity stake and provides an opportunity to accelerate the development of the Corvus pipeline in China
Oct 05, 2020
Enrollment in first three cohorts complete; final cohort now enrolling   with plans to initiate a pivotal study before year-end Anti-SARS-CoV-2 antibody response (IgG and IgM) to spike protein and RBD of SARS-CoV-2. Patients receive 0.3 or 1.0 mg/kg single dose of CPI-006 and antibody titers
Sep 17, 2020
Data is part of Genentech’s MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with atezolizumab Results consistent with prior studies, showing prolonged survival compared to chemotherapy and favorable safety data BURLINGAME,
Sep 11, 2020
Dr. Mitchell adds significant experience in cancer care, research and healthcare delivery as the Company advances pipeline into later-stage clinical development BURLINGAME, Calif. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical
Sep 10, 2020
Characterization of novel immunotherapy approach with CPI-006 and details of COVID-19 clinical trial results submitted for publication online at medRxiv.org Patients treated in first two cohorts of Phase 1 study had low pre-treatment titers of antibodies and produced robust antibody responses
Sep 08, 2020
BURLINGAME, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following investor conferences: HC Wainwright 22 nd Annual Investment Conference on September 14, 2020 at 4:00
Aug 04, 2020
BURLINGAME, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference . The presentation will be on Tuesday, August 11 from
Jul 30, 2020
Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call   Today at 4:30 p.m. ET / 1:30 p.m. PT   BURLINGAME, Calif. , July 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced
Jul 23, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , July 23, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30,
Jul 07, 2020
Approach stimulates immune response by activating B cells to enhance antibody production Safety and scientific basis supported by ongoing cancer clinical trial Study designed to evaluate anti-viral antibody response in up to 30 COVID-19 patients with mild to moderate symptoms Company to host
May 29, 2020
Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders Data Includes Additional Patients with Advanced Refractory Renal Cell Cancer, Supporting Earlier Results
May 27, 2020
BURLINGAME, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient
May 13, 2020
BURLINGAME, Calif. , May 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient
Apr 30, 2020
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the
Apr 22, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Mar 05, 2020
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the
Feb 28, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Feb 19, 2020
BURLINGAME, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Richard A. Miller , M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted
Feb 13, 2020
BURLINGAME, Calif. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated
Feb 01, 2020
BURLINGAME, Calif. , Feb. 01, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated